View in EDS PDF Full Text

Identification of a novel drug lead that inhibits HCV infection and cell-to-cell transmission by targeting the HCV E2 glycoprotein.

Saved in:
Bibliographic Details
Title: Identification of a novel drug lead that inhibits HCV infection and cell-to-cell transmission by targeting the HCV E2 glycoprotein.
Authors: Al Olaby RR; Department of Chemistry, The American University in Cairo, New Cairo, Egypt., Cocquerel L; Center for Infection and Immunity of Lille, CNRS-UMR8204/Inserm-U1019, Pasteur Institute of Lille, University of Lille North of France, Lille, France., Zemla A; Pathogen Bioinformatics, Lawrence Livermore National Laboratory, Livermore, CA, United States of America., Saas L; Center for Infection and Immunity of Lille, CNRS-UMR8204/Inserm-U1019, Pasteur Institute of Lille, University of Lille North of France, Lille, France., Dubuisson J; Center for Infection and Immunity of Lille, CNRS-UMR8204/Inserm-U1019, Pasteur Institute of Lille, University of Lille North of France, Lille, France., Vielmetter J; Protein Expression Center, Beckman Institute, California Institute of Technology, Pasadena, CA, United States of America., Marcotrigiano J; Department of Chemistry and Chemical Biology, Rutgers University, Piscataway, NJ, United States of America., Khan AG; Department of Chemistry and Chemical Biology, Rutgers University, Piscataway, NJ, United States of America., Vences Catalan F; Department of Medicine, Stanford University Medical Center, Stanford, CA, United States of America., Perryman AL; Department of Medicine, Division of Infectious Diseases, Center for Emerging & Re-emerging Pathogens, Rutgers University-New Jersey Medical School, Newark, NJ, United States of America., Freundlich JS; Department of Medicine, Division of Infectious Diseases, Center for Emerging & Re-emerging Pathogens, Rutgers University-New Jersey Medical School, Newark, NJ, United States of America; Department of Pharmacology and Physiology, Rutgers University-New Jersey Medical School, Newark, NJ, United States of America., Forli S; Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA, United States of America., Levy S; Department of Medicine, Stanford University Medical Center, Stanford, CA, United States of America., Balhorn R; Department of Applied Science, University of California Davis, Davis, CA, United States of America., Azzazy HM; Department of Chemistry, The American University in Cairo, New Cairo, Egypt.
Source: PloS one [PLoS One] 2014 Oct 30; Vol. 9 (10), pp. e111333. Date of Electronic Publication: 2014 Oct 30 (Print Publication: 2014).
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Links:
  – Type: pdflink
Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 25357246
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Identification of a novel drug lead that inhibits HCV infection and cell-to-cell transmission by targeting the HCV E2 glycoprotein.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Al+Olaby+RR%22">Al Olaby RR</searchLink>; Department of Chemistry, The American University in Cairo, New Cairo, Egypt.<br /><searchLink fieldCode="AU" term="%22Cocquerel+L%22">Cocquerel L</searchLink>; Center for Infection and Immunity of Lille, CNRS-UMR8204/Inserm-U1019, Pasteur Institute of Lille, University of Lille North of France, Lille, France.<br /><searchLink fieldCode="AU" term="%22Zemla+A%22">Zemla A</searchLink>; Pathogen Bioinformatics, Lawrence Livermore National Laboratory, Livermore, CA, United States of America.<br /><searchLink fieldCode="AU" term="%22Saas+L%22">Saas L</searchLink>; Center for Infection and Immunity of Lille, CNRS-UMR8204/Inserm-U1019, Pasteur Institute of Lille, University of Lille North of France, Lille, France.<br /><searchLink fieldCode="AU" term="%22Dubuisson+J%22">Dubuisson J</searchLink>; Center for Infection and Immunity of Lille, CNRS-UMR8204/Inserm-U1019, Pasteur Institute of Lille, University of Lille North of France, Lille, France.<br /><searchLink fieldCode="AU" term="%22Vielmetter+J%22">Vielmetter J</searchLink>; Protein Expression Center, Beckman Institute, California Institute of Technology, Pasadena, CA, United States of America.<br /><searchLink fieldCode="AU" term="%22Marcotrigiano+J%22">Marcotrigiano J</searchLink>; Department of Chemistry and Chemical Biology, Rutgers University, Piscataway, NJ, United States of America.<br /><searchLink fieldCode="AU" term="%22Khan+AG%22">Khan AG</searchLink>; Department of Chemistry and Chemical Biology, Rutgers University, Piscataway, NJ, United States of America.<br /><searchLink fieldCode="AU" term="%22Vences+Catalan+F%22">Vences Catalan F</searchLink>; Department of Medicine, Stanford University Medical Center, Stanford, CA, United States of America.<br /><searchLink fieldCode="AU" term="%22Perryman+AL%22">Perryman AL</searchLink>; Department of Medicine, Division of Infectious Diseases, Center for Emerging & Re-emerging Pathogens, Rutgers University-New Jersey Medical School, Newark, NJ, United States of America.<br /><searchLink fieldCode="AU" term="%22Freundlich+JS%22">Freundlich JS</searchLink>; Department of Medicine, Division of Infectious Diseases, Center for Emerging & Re-emerging Pathogens, Rutgers University-New Jersey Medical School, Newark, NJ, United States of America; Department of Pharmacology and Physiology, Rutgers University-New Jersey Medical School, Newark, NJ, United States of America.<br /><searchLink fieldCode="AU" term="%22Forli+S%22">Forli S</searchLink>; Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA, United States of America.<br /><searchLink fieldCode="AU" term="%22Levy+S%22">Levy S</searchLink>; Department of Medicine, Stanford University Medical Center, Stanford, CA, United States of America.<br /><searchLink fieldCode="AU" term="%22Balhorn+R%22">Balhorn R</searchLink>; Department of Applied Science, University of California Davis, Davis, CA, United States of America.<br /><searchLink fieldCode="AU" term="%22Azzazy+HM%22">Azzazy HM</searchLink>; Department of Chemistry, The American University in Cairo, New Cairo, Egypt.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101285081%22">PloS one</searchLink> [PLoS One] 2014 Oct 30; Vol. 9 (10), pp. e111333. <i>Date of Electronic Publication: </i>2014 Oct 30 (<i>Print Publication: </i>2014).
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Research Support, Non-U.S. Gov't
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Public+Library+of+Science%22">Public Library of Science </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101285081 <i>Publication Model: </i>eCollection <i>Cited Medium: </i>Internet <i>ISSN: </i>1932-6203 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2219326203%22">19326203 </searchLink><i>NLM ISO Abbreviation: </i>PLoS One <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=25357246
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1371/journal.pone.0111333
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: e111333
    Titles:
      – TitleFull: Identification of a novel drug lead that inhibits HCV infection and cell-to-cell transmission by targeting the HCV E2 glycoprotein.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Al Olaby RR
      – PersonEntity:
          Name:
            NameFull: Cocquerel L
      – PersonEntity:
          Name:
            NameFull: Zemla A
      – PersonEntity:
          Name:
            NameFull: Saas L
      – PersonEntity:
          Name:
            NameFull: Dubuisson J
      – PersonEntity:
          Name:
            NameFull: Vielmetter J
      – PersonEntity:
          Name:
            NameFull: Marcotrigiano J
      – PersonEntity:
          Name:
            NameFull: Khan AG
      – PersonEntity:
          Name:
            NameFull: Vences Catalan F
      – PersonEntity:
          Name:
            NameFull: Perryman AL
      – PersonEntity:
          Name:
            NameFull: Freundlich JS
      – PersonEntity:
          Name:
            NameFull: Forli S
      – PersonEntity:
          Name:
            NameFull: Levy S
      – PersonEntity:
          Name:
            NameFull: Balhorn R
      – PersonEntity:
          Name:
            NameFull: Azzazy HM
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 30
              M: 10
              Text: 2014 Oct 30
              Type: published
              Y: 2014
          Identifiers:
            – Type: issn-electronic
              Value: 1932-6203
          Numbering:
            – Type: volume
              Value: 9
            – Type: issue
              Value: 10
          Titles:
            – TitleFull: PloS one
              Type: main
ResultId 1